Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
CLPT reported a Form 144 notice to sell 16,000 shares of Common Stock. The shares are described as restricted stock vesting under a registered plan with a vesting date of 05/16/2025. The filing lists the transaction on NASDAQ and identifies the transaction type as compensation.
ClearPoint Neuro, Inc. disclosure: MAK Capital Fund LP, MAK Capital One LLC and Michael A. Kaufman report 1,901,489 shares of Common Stock beneficially owned, representing 6.3% of the class. The calculation is based on holdings as of 05/15/2026 and 29,989,563 shares outstanding as of May 7, 2026.
The filing identifies shared voting and dispositive power over the 1,901,489 shares and lists principal business addresses for the reporting persons.
ClearPoint Neuro, Inc. reports first-quarter 2026 results showing strong top-line growth but continued operating losses. Total revenue rose to $12.1 million from $8.5 million a year earlier, a 43% increase, driven by higher neurosurgery navigation, therapy, and capital equipment sales, including contributions from the IRRAflow and Prism platforms.
Biologics and drug delivery revenue was stable at $4.8 million, while neurosurgery navigation and therapy revenue jumped 80% to $5.9 million and capital equipment and software revenue rose 177% to $1.4 million. Gross margin improved to 64% from 60% as lower excess and obsolete inventory charges offset higher volumes.
Operating expenses grew sharply as the company invested in research, sales, and infrastructure following the IRRAS acquisition. Research and development costs increased to $4.5 million, sales and marketing to $6.7 million, and general and administrative to $5.0 million. Net loss widened to $9.6 million from $6.0 million, or $0.32 per share versus $0.22 per share. Cash, cash equivalents, and restricted cash totaled $36.5 million at quarter-end, and management believes current liquidity is sufficient for at least twelve months under its forecasts.
ClearPoint Neuro, Inc. reports first-quarter 2026 results showing strong top-line growth but continued operating losses. Total revenue rose to $12.1 million from $8.5 million a year earlier, a 43% increase, driven by higher neurosurgery navigation, therapy, and capital equipment sales, including contributions from the IRRAflow and Prism platforms.
Biologics and drug delivery revenue was stable at $4.8 million, while neurosurgery navigation and therapy revenue jumped 80% to $5.9 million and capital equipment and software revenue rose 177% to $1.4 million. Gross margin improved to 64% from 60% as lower excess and obsolete inventory charges offset higher volumes.
Operating expenses grew sharply as the company invested in research, sales, and infrastructure following the IRRAS acquisition. Research and development costs increased to $4.5 million, sales and marketing to $6.7 million, and general and administrative to $5.0 million. Net loss widened to $9.6 million from $6.0 million, or $0.32 per share versus $0.22 per share. Cash, cash equivalents, and restricted cash totaled $36.5 million at quarter-end, and management believes current liquidity is sufficient for at least twelve months under its forecasts.
ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% from $8.5 million a year earlier, driven by IRRAflow contributions and strong device demand. Organic revenue grew 16%, with organic devices up 25%, and gross margin improved to 64% from 60%.
Neurosurgery navigation, therapy and access revenue rose 80% to $5.9 million, while capital equipment and software revenue climbed 177% to $1.4 million. Operating expenses increased 44% to $16.2 million, reflecting the IRRAS acquisition and higher personnel and occupancy costs, resulting in a net loss of $9.6 million (–$0.32 per share).
The company ended March 31, 2026 with $35.6 million in cash and cash equivalents, down from $45.9 million at year-end, after using $8.0 million in cash for operating activities and $2.0 million for taxes on equity awards. ClearPoint issued a 2026 revenue outlook of $52.0–$56.0 million and highlighted integration of the IRRAflow portfolio, more than 60 active biopharma partners, new FDA clearance for the Velocity Alpha MR High Speed Surgical Drill System, a Health Canada license for its navigation system, and its first commercial drug delivery case in Asia-Pacific.
ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% from $8.5 million a year earlier, driven by IRRAflow contributions and strong device demand. Organic revenue grew 16%, with organic devices up 25%, and gross margin improved to 64% from 60%.
Neurosurgery navigation, therapy and access revenue rose 80% to $5.9 million, while capital equipment and software revenue climbed 177% to $1.4 million. Operating expenses increased 44% to $16.2 million, reflecting the IRRAS acquisition and higher personnel and occupancy costs, resulting in a net loss of $9.6 million (–$0.32 per share).
The company ended March 31, 2026 with $35.6 million in cash and cash equivalents, down from $45.9 million at year-end, after using $8.0 million in cash for operating activities and $2.0 million for taxes on equity awards. ClearPoint issued a 2026 revenue outlook of $52.0–$56.0 million and highlighted integration of the IRRAflow portfolio, more than 60 active biopharma partners, new FDA clearance for the Velocity Alpha MR High Speed Surgical Drill System, a Health Canada license for its navigation system, and its first commercial drug delivery case in Asia-Pacific.
ClearPoint Neuro, Inc. ownership update: a group led by Bigger Capital reports beneficial holdings in Common Stock.
As of April 20, 2026, Bigger Capital beneficially owned 1,361,644 shares (approximately 4.54% of the class). District 2 Capital Fund beneficially owned 341,696 shares (approximately 1.14%). Mr. Michael Bigger may be deemed to beneficially own a combined 2,261,340 shares (~7.54%), including shares attributed to family members and an IRA. The percentages are calculated using 29,986,016 shares outstanding as of March 23, 2026.
ClearPoint Neuro, Inc. is asking stockholders to vote at a virtual-only 2026 Annual Meeting on May 20, 2026 at 10:00 a.m. Pacific Time. Holders of 29,986,016 common shares as of March 23, 2026 may participate.
Stockholders will elect seven directors, ratify Cherry Bekaert LLP as independent auditor, cast an advisory say-on-pay vote on executive compensation, and consider approval of the Seventh Amended and Restated 2013 Incentive Compensation Plan. The revised plan would add 1,000,000 shares, increasing the total plan share reserve to 7,806,250, which the company notes is about 3% of fully diluted shares.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director R. John Fletcher received 1,270 shares of common stock as a grant. The shares were issued at $9.10 per share under the company’s incentive compensation plan as payment of fees owed under the Non-Employee Director Compensation Plan.
Following this compensation-related issuance, Fletcher directly holds 117,932 shares of ClearPoint Neuro common stock.
Girin Pascal E R reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro director Pascal E. R. Girin received 755 shares of Common Stock as compensation. The shares were granted at $9.10 per share under the company’s Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed under the Non-Employee Director Compensation Plan. Following this award, Girin directly holds 98,206 shares of ClearPoint Neuro common stock.